Login
$KYMR
$125.10 -$2.47 (1.94%) Live

$KYMR 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition

Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial

05 Aug 2026 8-K: Results of Operations and Financial Condition

Enrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026

27 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Dr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio

25 Jun 2026 8-K: Regulation FD Disclosure; Other Events

BROADEN2 enrollment completed nearly six months ahead of anticipated timelines

24 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Kymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 24, 2026 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, eac...

08 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

30 Apr 2026 8-K: Results of Operations and Financial Condition

KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively

27 Mar 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

Section 8 of Article VI of the Second Amended and Restated Bylaws of the Corporation (the “Bylaws”) is hereby amended and restated in its entirety as follows:

26 Feb 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement +1 more

Kymera Therapeutics, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows:

26 Feb 2026 8-K: Results of Operations and Financial Condition

KT-621 (STAT6) BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027

13 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027

10 Dec 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Je...

08 Dec 2025 8-K: Regulation FD Disclosure

Exhibit 99.1 KT-621, Oral STAT6 Degrader, Phase 1b Results 1

08 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis

04 Nov 2025 8-K: Results of Operations and Financial Condition

Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025

03 Sep 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Watertown, Mass. (September 3, 2025) – Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the a...

11 Aug 2025 8-K: Results of Operations and Financial Condition

Reported positive KT-621 (STAT6) Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile

27 Jun 2025 8-K: Entry into a Material Definitive Agreement; Other Events

Kymera Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), for whom Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Je...

27 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

Kymera Therapeutics, Inc. (the “Company”) held its Annual Meeting of Shareholders on June 25, 2025 (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders considered and voted on the three proposals set forth below, eac...

25 Jun 2025 8-K: Regulation FD Disclosure; Other Events

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support